Shenzhen Salubris Pharmaceuticals Co., Ltd.
002294
Rangering i aksjer
#3422
Established in 1998 and headquartered in Shenzhen, China, Shenzhen Salubris... Established in 1998 and headquartered in Shenzhen, China, Shenzhen Salubris Pharmaceuticals Co., Ltd. operates across the entire pharmaceutical value chain, from research and development to manufacturing and sales. The company primarily focuses on critical therapeutic areas within China, including cardiovascular, anti-diabetic, anti-cancer, and orthopedic medicine. Its diverse product portfolio features a variety of cardiovascular and cerebrovascular medications, such as allisartan isoproxil and clopidogrel bisulfate tablets, alongside injectable options like bivalirudin. A significant offering is the recombinant SeV-hFGF2/dF Injection, specifically developed for the treatment of diabetic foot disease. Salubris also manufactures anti-tumor and orthopedic drugs. Furthermore, its anti-infective range encompasses numerous injectable antibiotics, including ceftazidime and ceftriaxone sodium, as well as oral preparations such as azithromycin dispersible and levetiracetam tablets. The firm also innovates in biotechnological drugs, developing recombinant proteins and monoclonal antibodies. Complementing its domestic operations, Shenzhen Salubris Pharmaceuticals engages in the import, in-licensing, and out-licensing of medicines, particularly for European markets.
Aksjekurs
$4.48
Markedsverdi
$4.99B
Endring (1 dag)
-5.20%
Endring (1 år)
-41.89%
Land
CN
Handel Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294)
Kategori
Healthcare
Inntekter for Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294)
Inntekter i Jun 2026 TTM: $95.41M
Ifølge Shenzhen Salubris Pharmaceuticals Co., Ltd. sine nyeste økonomiske rapporter er selskapets nåværende resultat $95.41M. I 2024 hadde selskapet et resultat på $86.66M, en nedgang sammenlignet med resultatet i 2023, som var $90.66M. Resultatet som vises på denne siden er resultat før renter og skatt, eller EBIT.
Inntektshistorikk for Shenzhen Salubris Pharmaceuticals Co., Ltd. fra 2006 til 2026
Inntekter ved slutten av hvert år
| År | Inntekter | Endre |
|---|---|---|
| 2026 (TTM) | $95.41M | 1.77% |
| 2025 | $93.75M | 8.18% |
| 2024 | $86.66M | -4.42% |
| 2023 | $90.66M | -12.38% |
| 2022 | $103.47M | 9.64% |
| 2021 | $94.38M | 986.53% |
| 2020 | $8.69M | -92.90% |
| 2019 | $122.26M | -50.71% |
| 2018 | $248.05M | -5.91% |
| 2017 | $263.64M | 10.90% |
| 2016 | $237.72M | 3.50% |
| 2015 | $229.68M | 16.86% |
| 2014 | $196.54M | 22.09% |
| 2013 | $160.97M | 33.79% |
| 2012 | $120.32M | 59.83% |
| 2011 | $75.28M | 19.59% |
| 2010 | $62.95M | 72.35% |
| 2009 | $36.52M | 96.81% |
| 2008 | $18.56M | 76.92% |
| 2007 | $10.49M | 123.31% |
| 2006 | $4.70M | 0.00% |
Inntekter for lignende selskaper eller konkurrenter
| Selskap | Inntekter | Forskjell i inntekter | Land |
|---|---|---|---|
| $3.62B | 3,693.17% |
US
|
|
| $4.11B | 4,206.59% |
FR
|
|
| $2.19B | 2,197.71% |
JP
|
|
| $1.59B | 1,566.52% |
US
|
|
| $738.72M | 674.27% |
CH
|
